Less than 10% of individuals that would benefit from weight-loss injections like Wegovy have access to them, caution the WHO as it releases its initial recommendations on the medications.
Given over a billion individuals worldwide now classified as obese, it is urging increased and just availability to this class of drugs.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that obesity is a chronic disease that can be addressed with thorough and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are key hurdles to universal access to the treatments that can assist patients in reducing considerable weight, says the organization.
Skinny Jab Shortage
Despite the present best projected scenario, the manufacturing of these medications could only cover around 100 million people – under 10% of the global need, as stated by the health organization.
The guideline calls on governments and firms to widen availability, by measures including voluntary licensing.
The intellectual property rights on a key compound – the core component of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.
The Way Obesity Injections Function
These medications mimick a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so people eat less.
Patients typically begin shedding pounds within a few weeks of commencing the regular doses.
Evidence indicates people may regain a significant portion after a year of halting the medication, when their normal hunger come back.
To be overweight or obese increases your risk for developing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight affects people in all nations and was associated with 3.7 million deaths worldwide in 2024, according to the health agency.
